145 related articles for article (PubMed ID: 21284506)
1. VEGF as a biomarker for metastatic uveal melanoma in humans.
Barak V; Pe'er J; Kalickman I; Frenkel S
Curr Eye Res; 2011 Apr; 36(4):386-90. PubMed ID: 21284506
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-1 as a predictive biomarker for metastatic uveal melanoma in humans.
Frenkel S; Zloto O; Pe'er J; Barak V
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):490-3. PubMed ID: 23197685
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.
Kadkol SS; Lin AY; Barak V; Kalickman I; Leach L; Valyi-Nagy K; Majumdar D; Setty S; Maniotis AJ; Folberg R; Pe'er J
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):802-6. PubMed ID: 16505010
[TBL] [Abstract][Full Text] [Related]
4. sIL-2R- an Immuno-biomarker for Prediction of Metastases in Uveal Melanoma.
Barak V; Kalickman I; Pe'er J
Anticancer Res; 2022 Mar; 42(3):1447-1453. PubMed ID: 35220238
[TBL] [Abstract][Full Text] [Related]
5. "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma.
Reiniger IW; Schaller UC; Haritoglou C; Hein R; Bosserhoff AK; Kampik A; Mueller AJ
Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1161-6. PubMed ID: 15906071
[TBL] [Abstract][Full Text] [Related]
6. Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker.
Barak V; Frenkel S; Valyi-Nagy K; Leach L; Apushkin MA; Lin AY; Kalickman I; Baumann NA; Pe'er J; Maniotis AJ; Folberg R
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4399-402. PubMed ID: 17898257
[TBL] [Abstract][Full Text] [Related]
7. Trends in liver function tests: a comparison with serum tumor markers in metastatic uveal melanoma (part 2).
Hendler K; Pe'er J; Kaiserman I; Baruch R; Kalickman I; Barak V; Frenkel S
Anticancer Res; 2011 Jan; 31(1):351-7. PubMed ID: 21273623
[TBL] [Abstract][Full Text] [Related]
8. Serum markers to detect metastatic uveal melanoma.
Barak V; Frenkel S; Kalickman I; Maniotis AJ; Folberg R; Pe'er J
Anticancer Res; 2007; 27(4A):1897-900. PubMed ID: 17649791
[TBL] [Abstract][Full Text] [Related]
9. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
[TBL] [Abstract][Full Text] [Related]
10. Regulation of VEGF-A in uveal melanoma.
el Filali M; Missotten GS; Maat W; Ly LV; Luyten GP; van der Velden PA; Jager MJ
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2329-37. PubMed ID: 20042655
[TBL] [Abstract][Full Text] [Related]
11. Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma.
Barisione G; Fabbi M; Gino A; Queirolo P; Orgiano L; Spano L; Picasso V; Pfeffer U; Mosci C; Jager MJ; Ferrini S; Gangemi R
JAMA Ophthalmol; 2015 Sep; 133(9):1013-21. PubMed ID: 26068448
[TBL] [Abstract][Full Text] [Related]
12. Hepatic Ultrasonography for Surveillance in Patients With Uveal Melanoma.
Choudhary MM; Gupta A; Bena J; Emch T; Singh AD
JAMA Ophthalmol; 2016 Feb; 134(2):174-80. PubMed ID: 26633182
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
Reiniger IW; Wolf A; Welge-Lüssen U; Mueller AJ; Kampik A; Schaller UC
Am J Ophthalmol; 2007 Apr; 143(4):705-7. PubMed ID: 17386288
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC
Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465
[TBL] [Abstract][Full Text] [Related]
15. ME20-S as a Potential Biomarker for the Evaluation of Uveal Melanoma.
Bande MF; Santiago M; Mera P; Piulats JM; Blanco MJ; Rodríguez-Álvarez MX; Capeans C; Piñeiro A; Pardo M
Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7007-11. PubMed ID: 26523384
[TBL] [Abstract][Full Text] [Related]
16. Liver function tests in metastatic uveal melanoma.
Kaiserman I; Amer R; Pe'er J
Am J Ophthalmol; 2004 Feb; 137(2):236-43. PubMed ID: 14962411
[TBL] [Abstract][Full Text] [Related]
17. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1).
Barak V; Kaiserman I; Frenkel S; Hendler K; Kalickman I; Pe'er J
Anticancer Res; 2011 Jan; 31(1):345-9. PubMed ID: 21273622
[TBL] [Abstract][Full Text] [Related]
18. GDF-15: a novel serum marker for metastases in uveal melanoma patients.
Suesskind D; Schatz A; Schnichels S; Coupland SE; Lake SL; Wissinger B; Bartz-Schmidt KU; Henke-Fahle S
Graefes Arch Clin Exp Ophthalmol; 2012 Jun; 250(6):887-95. PubMed ID: 21881845
[TBL] [Abstract][Full Text] [Related]
19. DJ-1: a promising marker in metastatic uveal melanoma.
Chen LL; Tian JJ; Su L; Jing Y; Zhang SC; Zhang HX; Wang XQ; Zhu CB
J Cancer Res Clin Oncol; 2015 Feb; 141(2):315-21. PubMed ID: 25129821
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma.
Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Thiel E; Foerster MH; Keilholz U
Oncology; 2011; 80(1-2):57-62. PubMed ID: 21625180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
